G. Russell BellChief Scientific Officer Emeritus
Beckman Coulter, Inc.
President, Beckman Coulter Foundation
Emeritus Petit Institute Advisory Board Member
G. Russell “Russ” Bell, 64, retired from Beckman Coulter, having served as senior vice president and chief scientific officer. He joined the company as president and CEO of Hybritech Incorporated, the former subsidiary of Eli Lilly and Company, acquired by Beckman Instruments, Inc. in January 1996. Previously Bell held executive positions with du Pont and was president of Jacksonville Reference Laboratories. Throughout his career he spearheaded the development of many diagnostic products in cancer, men’s and women’s health and cardiovascular disease. He is active volunteering with Cancer Treatment Center at St. Peter’s Hospital, Helena, Montana.
Born in Atlanta, Ga., Bell received his bachelor of science degree in applied biology (1969) and his master of science (1970) from Georgia Tech and his doctorate in biochemistry in 1973 from the University of Georgia where he was a National Science Foundation fellow. Bell is a member of Phi Kappa Phi, scholastic honor society. He has served on the advisory boards of the Petit Institute of Bioscience and Bioengineering at Georgia Tech, the Wallace G. Coulter Foundation, and the Betty Irene Moore School of Nursing at UC Davis. He has been president of the Beckman Coulter Foundation since its formation in September 2007.
Bell and his wife, Sharon, reside in Clancy, Montana.
Life Science Partner, Inc.
Dr. Thomas H. Callaway is Chief Executive Officer and serves on the board of AerovectRx, an aerosol vaccine delivery company which is commercializing technology developed at the Centers for Disease Control and Prevention. Callaway is the founder and president of Life Science Partner, an executive search firm focused exclusively on recruiting scientific and managerial leaders for the life sciences industry including companies developing medical devices, diagnostics, biopharmaceuticals and convergent technologies. He is also a founding partner of an early stage seed fund, Georgia Venture Partners. Georgia Venture Partners was established in 2004 to make seed and early-stage investments in life sciences enterprises related to Georgia. As an investor, he takes an active role in the management of the portfolio start-ups. He is a former partner with Fuqua Ventures (a life science and technology venture capital fund) and two leading recruiting firms Russell Reynolds and Korn/Ferry International. Active in the investing community of the southeast, Callaway is the vice chairman of Georgia BIO, the region's largest life science organization, and serves on the boards of the Atlanta Venture Forum and Southeast BIO. Before moving to Atlanta, he held the position of director of commercial development for SyStemix. There he was responsible for business development and marketing for the firm's proprietary stem cell technology for bone marrow rescue of patients following high dose chemotherapy. He began his biotechnology career at Roche Diagnostics and Roche Molecular Systems. During his tenure at Roche, he developed and executed a global marketing plan for polymerase chain reaction (PCR) diagnostics technology, a Noble-prize winning solution for sleuthing out specific sequences of DNA and commercializing the tools to map the human genome. Callaway earned a medical degree from Vanderbilt University School of Medicine. He holds an MBA and undergraduate degree from Duke University. He can be reached at firstname.lastname@example.org.
Coury Consulting Services
Art Coury holds a B.S. degree in chemistry from the University of Delaware (1962), a Ph.D. in organic chemistry (1965), and an M.B.A. (1980) from the University of Minnesota. His industrial career includes positions as: senior research chemist at General Mills, Inc. (1965-1976), director, Polymer Technology and Research Fellow at Medtronic, Inc. (1976-1993), vice president, research and chief scientific officer at Focal, Inc. (1993-2000), and vice president, Biomaterials Research at Genzyme Corporation (2000-June, 2008). He currently is a consultant. His career focus has been polymeric biomaterials for medical products such as implantable electronic devices, hydrogel-based devices, and drug delivery systems. He holds over fifty distinct patents and has published and presented widely in his field. His teaching positions have included adjunct or affiliate appointments at the University of Minnesota, the Harvard-MIT Graduate Program in Health Sciences and Technology, and the University of Trento, Italy. His professional service has included: Chair, Minnesota Section, American Chemical Society (1989-1990); President, Society for Biomaterials, USA (1999-2000); President, American Institute for Medical and Biological Engineering (2003-2004) and membership on several university, society, and corporate advisory boards. His recent recognitions have included the delivery of distinguished lectureships, receipt of the 2007 Innovation and Technology Development Award of the Society for Biomaterials, being named as one of "100 Notable People in the Medical Device Industry" by MD&DI magazine, 2008, induction into the National Academy of Engineering, USA, 2009, and induction on the University of Delaware "Wall of Fame," 2010.
Tech Square Ventures
Erin Dasher is an attorney and business professional with over 15 years of experience in venture, private equity, M&A, and investment management. Most recently, Dasher served as General Counsel of STW Fixed Income Management for seven years and helped to grow assets under management to over $12 billion. Before leaving the firm, she co-led the sale of STW to Schroders. Prior to STW, Dasher was as an attorney at O’Melveny & Myers and Sheppard, Mullin, Richter & Hampton, where she led transactions in venture capital, public and private offerings, M&A, joint ventures, and commercial transactions.
Dasher grew up in Silicon Valley, and her passion is working with entrepreneurs and early stage technology companies. Since moving to Atlanta, Dasher has advised seed and early stage venture funds, entrepreneurs, startups, and emerging growth companies. She is a member of the Atlanta ARCS Foundation which is dedicated to supporting American leadership and advancement in science and technology. Dasher and her husband, Karl, are actively involved in the Georgia Tech community and are supporters of local scientific research and scholarship. Dasher is a graduate of University of California, Santa Cruz and graduated magna cum laude from Cornell Law School.
Deborah DeanExecutive Vice President
Deborah Dean serves as Executive Vice President of MiMedx. Dean is an executive with C-Level expertise and experience in operations, general management, sales and marketing, business development, key account management, technology, data integration, analytics, applications development, informatics, and technical infrastructure.
Prior to joining MiMedx, Dean was President and Chief Operating Officer of HolaDoctor, the Number One Hispanic Health Digital Site and exclusive partner to Univision.com. During her tenure at HolaDoctor, she played a key role in the transformation of the company from a primarily translation and research consulting company to a health information company delivering over 12 million digital impressions per month. Immediately prior to her association with HolaDoctor, Dean served with Matria Healthcare from 2005 to 2008. Prior to joining Matria, Dean was Senior Vice President of Research and Development and General Manager of the Provider Business for Quovadx, Inc., a leading healthcare integration company. Dean earned a bachelor’s degree in Health Services Administration from Arkansas State University.
David DoddPresident, CEO & Managing Director
Prior to forming RiversEdge BioVentures LLC, David Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies. Recently, Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.). In addition, Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company. From June 2000 to July 2006, Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. Dodd holds a bachelor of science and master of science from Georgia State University, and completed the Harvard Business School Advanced Management Program.
Goodman Espy, IIIPresident
Goodman B. "G.B." Espy, M.D. received his bachelor's degree in mechanical engineering from Georgia Tech in 1957. He is the only known co-op student to have been elected to both ODK and the ANAK Society while at Georgia Tech. After graduation, he taught math as a graduate assistant and worked at the Georgia Tech Research Station on a number of medical projects before entering Tulane Medical School in 1958. In 1962 he received his M.D. degree, which was followed by four years of OB-GYN residency training at Tulane. Espy then entered the U.S. Army.
In 1967, he founded OB-GYN Associates in Marietta, Georgia. He has delivered more than 12,000 babies in his career, and is credited with having delivered more babies than any other physician in Georgia. In 1993, he co-authored a new surgical approach for laparoscopic hysterectomies, which was reported in several medical publications. Overall, Espy has performed more than 10,000 surgical procedures.
During the Kosovo War, in 1999, Espy went to refugee camps in Albania, and has since been very active in obtaining medical equipment for Albanians in an effort to upgrade what he calls "a deplorable example of the medical environment in which those less fortunate than we live." Under his leadership, his medical practice has funded more than thirty scholarships during the last twenty-five years, for students in need of an education in Europe and the United States.
Espy served on the Georgia Tech Advisory Board from 1978 to 1986, and from 1988 until 1998, he was a member of the Woodruff School of Mechanical Engineering's advisory board. Since 1995, he has served on the external advisory board for the Petit Institute for Bioengineering and Biosciences at Georgia Tech. In 2001, Espy was the recipient of the Beta Theta Pi National Leadership and Service Award. In 2002, he was given a Community Service Award by Channel 11, and in 2003 he received the Dr. Jack A. Raines Humanitarian Award from the Medical Association of Georgia. That award was given for "outstanding humanitarian contributions to his fellow man, community, country, and world community beyond the practice of medicine." He is on the board of directors of several organizations.
Espy has a special interest in running, having run more than sixty marathons, including the last twenty-five New York marathons.
Chris FairManaging Director and Founder
Chris Fair has over 25 years of senior executive management and entrepreneurial experience focused in medical device and biologic platforms. Fair’s operational experience covers areas such as strategic market plans, product development, sales, marketing, finance, and the ability to take platform technologies from creation through commercialization in the most efficient pathway possible.
Fair began his medical device career at DePuy, where alongside a small team of personnel, helped to build the spine franchise from a $10M business to a $350M business within a 9 year timeframe. Fair then served as Vice President Sales and Marketing, St. Francis Medical Technologies where he was responsible for the U.S. launch of the XSTOP device. The launch of the XSTOP achieved $43M in U.S. revenue in the first 11 months and resulted in the largest medical device multiple with an acquisition price of $725M to Kyphon. After St. Francis, Fair served as the COO of MedShape Solutions, an innovative shape memory polymer and nitinol company, where he remains an active investor. Fair went on to start Amniox Medical, a spin out company based on amniotic tissue therapies for markets outside of ophthalmology. In the company’s first year of operation, Amniox surpassed all revenue targets and achieved profitability. Most recently, Fair served as President and CEO of a private equity backed spine venture, Amendia/Spinal Elements, a $100M + spinal implant company based in Carlsbad, CA.
Fair serves on the boards of Spinal Elements, CellectCell, and 510Kardiac. Fair received his BS Business Administration from the University of Richmond.
Chris GemmitiFounder and Managing Director
Ridgewood Consulting LLC
Chris is the founder and managing director of a strategic and technical consulting compnay focusing on tissue engineering and regenerative medicine technologies over a range of therapeutic areas. He has 18 years experience in regenerative medicine, through various roles in academia and industry. He is also the head of operations for Sentien Biotechnologies, Inc., and leads cross-functional operations for clinical-stage cell therapy. Previously, Chris was the product director at Organogenesis, Inc. where he was responsible for the launch of a new living cellular sheet, GINTUIT™. GINTUIT™ marked the first-ever approval (2012) of a manufactured allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA. He maintains leadership positions with the Tissue Engineering Regenerative Medicine Interational Society (TERMIS) and Alliance for Regenerative Medicine (ARM). Chris holds a B.S. in Biomedical Engineering from The Johns Hopkins University and Ph.D. in Biomedical Engineering jointly conferred by the Georgia Tech and Emory University.
Linda GriffithSchool of Engineering Teaching Innovation Professor of Biological and Mechanical Engineering
Massachusetts Institute of Technology
Director, Center for Gynepathology Research
Linda G. Griffith, Ph.D., is the School of Engineering Teaching Innovation Professor of Biological and Mechanical Engineering and MacVicar Fellow at MIT, where she directs the Center for Gynepathology Research and the DARPA/NIH-funded Human Physiome on a Chip Program. Griffith received a bachelor's degree from Georgia Tech and a Ph.D. degree from the University of California at Berkeley, both in chemical engineering. Griffith’s research is in the field of regenerative medicine and tissue engineering. Her laboratory, in collaboration with J. Upton and C. Vacanti, was the first to combine a degradable scaffold with donor cells to create tissue-engineered cartilage in the shape of a human ear. The 3D printing process she co-invented for creation of complex scaffolds is used for manufacture of FDA-approved scaffolds for bone regeneration. She is also a pioneer in devising ways to control nano-scale stimulation of cells by molecular cues, and in creation of 3D tissue models for drug development. Her work has been featured on television documentary shows including Scientific American Frontiers. She is a member of the National Academy of Engineering, and the recipient of a MacArthur Foundation Fellowship, the Popular Science Brilliant 10 Award, NSF Presidential Young Investigator Award, the MIT Class of 1960 Teaching Innovation Award, Radcliffe Fellow, and several awards from professional societies. She has served as a member of the advisory councils for the National Institute for Dental and Craniofacial Research and the National Institute of Arthritis, Musculoskeletal and Skin Diseases at NIH. As chair of the undergraduate curriculum committee for biological engineering at MIT, she led development of the new Biological Engineering SB degree program, which was approved in 2005 as MIT’s first new undergraduate major in 39 years.
Lucky JainChair, Department of Pediatrics at Emory University School of Medicine
Chief Academic Officer, Children's Healthcare of Atlanta
Executive Director, Emory + Children's Pediatric Institute
Lucky Jain, M.D., MBA, is the chair of the Department of Pediatrics at Emory University School of Medicine; chief academic officer of Children's Healthcare of Atlanta; and executive director of Emory + Children's Pediatric Institute.
Jain, who is the Richard W. Blumberg Professor, joined Emory in 1994 as associate professor and was promoted to professor in 2001. Jain was a member of the inaugural class of the Woodruff Leadership Academy and received an executive MBA from the Goizueta Business School at Emory in 2004. In 2006, he was appointed medical director of Emory-Children's Center and executive vice chair of the Department of Pediatrics.
Jain received his medical degree and completed his residency at the University of Rajasthan in Jaipur, India, and his fellowship in neonatal-perinatal medicine at the University of Illinois at Chicago. He is a specialist in respiratory disorders of the newborn. His research focuses on the physiology of lung sodium and fluid transport, and on strategies to enhance lung fluid clearance, particularly in late preterm infants and those born by elective Cesarean section. His lab is credited with elucidation of the role steroids play in fetal lung fluid clearance and the resulting multicenter trial of antenatal steroid treatment in late preterm gestations.
In 2016, Jain was elected scientific chairman of the International Neonatology Association. He is editor of the journal Clinics in Perinatology and has more than 150 publications. He is a member of several national scientific organizations including the American Thoracic Society, American Physiologic Society, Society for Pediatric Research and American Pediatric Society.
Anjali KumarDue Diligence Lead, Corporate Development
Anjali Kumar has had nearly 20 years of experience with increasing responsibility in the biopharmaceutical industry, and is currently the Due Diligence Lead, Corporate Development for Shire Pharmaceuticals. She previously served as the vice president, nonclinical R&D and scientific affairs at Flexion Therapeutics, Inc. She has a strong scientific background and drug discovery and development experience gained in large pharmaceutical and small biotech company environments. She has experience advancing several small molecules and proteins into initial clinical development and continuing to support them through later stages of development and eventual regulatory approval. Kumar has worked in the area of inflammation in musculoskeletal, respiratory, and cardiovascular diseases. She was previously vice president of R&D at Clinquest, Inc. where she led the strategic drug development consulting team that worked on multiple programs in both the U.S. and in Europe. Prior to that, she was senior director, pharmacology at Critical Therapeutics, Inc. and principal scientist and project leader at Wyeth Research/Genetics Institute. She received her postdoctoral training at Pharmacia and Upjohn, Inc. She holds a Ph.D. in bioengineering from Georgia Institute of Technology and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology.
Bruce LavinHead of External Engagement and Policy, Neurology Unit
Bruce Lavin, M.D. is the head of external engagement and policy within the neurology unit of UCB, Inc. Lavin has 25 years of clinical experience and more than 15 years of industry experience, leading medical affairs and clinical development programs and divisions for major pharmaceutical companies in the areas of immunology, virology and anti-infectives. Most recently, Lavin was the vice president and therapeutic head for Bristol-Myers Squibb where he led the U.S. clinical and launch preparations for anti-virals in HIV, HCV, rheumatology, and transplant. Prior to Bristol-Myers Squibb, he held senior medical roles for both Novartis and Sanofi-Aventis in the areas of infectious disease, immunology, transplantation, virology and the central nervous system. Additionally, Lavin has a vast military career, currently serving as a medical doctor for the U.S. Navy Reserve. From 2009-2010, he provided medical care and support in a combat area during Operation Iraqi Freedom. Lavin holds a bachelor’s degree from the University of California Irvine and a master’s of public health from the University of California, Los Angeles. He received his medical degree from the F. Herbert School of Medicine at Uniformed Services University of the Health Sciences in Bethesda, Maryland.
Anthony Lee has over 18 years of experience in the medical device business. He is currently the president of Eyegenix LLC, a venture backed start-up developing a biosynthetic cornea for the treatment of corneal blindness. In 2011, Eyegenix and sister company Skai Ventures were awarded the statewide winner of the APEC 2011 Business Innovation Showcase. Prior to Eyegenix, Lee led the research and development team at Coalescent Surgical, Inc., a venture funded medical device startup focused on minimally invasive cardiovascular bypass and valve fixation. Coalescent Surgical was acquired by Medtronic, Inc. in 2004. Prior to his work at Coalescent, Lee led R&D efforts at two venture financed companies: Vivant Medical, which was acquired by Valley Lab/Tyco, and AneuRx, which was acquired by Medtronic Inc. Lee is a registered professional engineer in the state of California. He holds numerous U.S. and international patents with several pending. Lee received his BME and MSME from Georgia Tech in 1993 and 1995, respectively. He currently splits his time between San Francisco, CA and Honolulu, HI.
Kevin MaherDirector, Pediatric Cardiac Nanomedicine
Associate Director, Atlantic Pediatric Device Consortium
Emory University School of Medicine
Kevin Maher, M.D. graduated from the University of Maryland School of Medicine in 1991. He completed a residency and chief residency in pediatrics at Maryland and then went on the University of Michigan for a fellowship in pediatric cardiology. He completed further subspecialty training in cardiac intensive care and interventional catheterization at Thomas Jefferson University/DuPont Children’s Hospital. In 2004, Maher joined the pediatric cardiology group at Children’s Healthcare of Atlanta and Emory University School of Medicine. His primary clinical responsibilities are in the pediatric cardiac intensive care unit at Children’s. This unit cares for children from newborns through age 21 years and involves the pre and postoperative management of critical heart disease, including children with ventricular assist devices, extracorporeal support (ECMO) and cardiac transplantation. A significant amount of time is devoted to teaching and research. Maher’s research activities include neonatal CPR, cardiac biomarkers in children, development of novel therapies for congenital heart disease, and device development efforts. In an attempt to find new treatments for cardiomyopathy, he brought together researchers at Children's, Emory, and Georgia Tech, developing the first Pediatric Nanomedicine Center in the country. Maher works to develop collaborations with Georgia Tech, aiming to bring engineers into the field of pediatric research and development. To this end he is the director of Pediatric Cardiac Nanomedicine, the co-director of the Center for Pediatric Innovation and the co-director of the Atlantic Pediatric Device Consortium.
Robert (Bob) McNallyPresident and CEO
GeoVax Labs, Inc.
Bob McNally became president and CEO of GeoVax Labs, Inc., in April 2008, after serving on its board of directors since 2006. He was previously co-founder and CEO of Cell Dynamics, LLC. Cell Dynamics specialized in the recovery and GMP processing of human organs and tissues used for biotech and cellular medical therapies. During the period 1984 to 1998, McNally was co-founder and sr. vice president of clinical research for CryoLife, Inc., the market leader in transplantable human tissues including cryopreserved heart valves, veins, ligaments and tendons of the knee as well as a manufacturer of protein-derived surgical adhesives. McNally led and helped launch the company from startup through going public on the NASDAQ and NYSE. McNally received a bachelor of electrical engineering degree from Villanova University, and has a Ph.D. in biomedical engineering from the University of Pennsylvania. He has authored numerous patents and publications in the field of transplantable tissues and is a frequent speaker for business development in Georgia and student groups. Currently, McNally serves as a member of the advisory boards of the Petit Institute for Bioengineering and Bioscience and Dupree College of Management at the Georgia Institute of Technology. He is an elected fellow of the American Institute for Medical and Biological Engineering, is a past chairman for the Georgia Biomedical Partnership, a trade association, and is a recipient of the 2004 Biomedical Industry Growth Award for the state of Georgia.
Russell MedfordManaging Partner
The Salutramed Group, Inc.
Russell M. Medford, M.D., Ph.D. has served, since April 1, 2009, as chairman and president of Salutria Pharmaceuticals, Inc., a biopharmaceutical company. From 1995 to April 1, 2009, Medford served as president, chief executive officer and director of AtheroGenics, Inc., a publicly-held pharmaceutical company.
Medford serves on the Biotechnology Industry Organization Board of Directors and BIO Emerging Companies Section Governing Body, and he served as Chairman of the Georgia BioMedical Partnership from 2004 to 2007 and the Georgia Biotechnology Industry Organization Board of Directors. Medford was an associate professor of medicine and director of molecular cardiology at the Emory University School of Medicine, and currently holds the appointment of adjunct clinical professor of medicine. Medford received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine.
Pete PetitChairman and CEO
MiMedx Group, Inc.
Emeritus Petit Institute Advisory Board Member
Pete Petit is a successful entrepreneurial executive who has also managed several public companies as chairman and CEO. Therefore, his experience and perspectives are brought to the Petit Group’s investments.
Petit joined the MiMedx Group, Inc. as chairman of the board of directors, chief executive officer and president in February 2009. From May 2008 until he joined the company, Petit was the president of The Petit Group, LLC, a private investment company. Prior to that, Petit was the chairman and CEO of Matria Healthcare, Inc.
Matria Healthcare was a former subsidiary of Healthdyne, Inc., which Petit founded in 1971. Petit served as chairman and CEO of Healthdyne and some of its publicly traded subsidiaries after Healthdyne became a publicly traded company in 1981. Petit received his bachelor's degree in mechanical engineering and master of science degree in engineering mechanics from Georgia Tech, and an MBA degree in finance from Georgia State University. At Georgia Tech, Petit funded a professorial chair for "Engineering in Medicine," endowed the Petit Institute for Bioengineering and Bioscience, and assisted with the funding of the Biotechnology Building which bears his name. At Georgia State University, he assisted with the funding of the Science Center building which also bears his name. In 1994, he was inducted into the Technology Hall of Fame of Georgia. In 2007, he was inducted into the Georgia State Business Hall of Fame. Petit has previously served as a member of the board of directors of the Georgia Research Alliance, which is chartered by the state of Georgia to promote high technology and scientific development in the state.
Petit fully understands the entrepreneurial spirit and the associated trials and tribulations of growing businesses. The Petit Group seeks investment relationships in private corporations where its management and business expertise may be utilized in addition to its financial resources.
Brock ReeveExecutive Director
Harvard Stem Cell Institute
Brock Reeve is executive director of the Harvard Stem Cell Institute (HSCI). In partnership with the faculty directors, he has overall responsibility for the operations and strategy of the Institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases.
HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of the executive committee, HSCI invests in scientific research and its faculty has grown to include over 300 principal and affiliated members. The Institute is engaged with several leading pharmaceutical companies and foundations in joint research projects and its faculty have founded several stem cell-related startup companies and serve on leading scientific advisory boards.
Brock came to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences. Brock received a B.A. and MPhil from Yale University and an MBA from Harvard Business School.
Fred SanfilippoDirector, Healthcare Innovation Program
Dr. Fred Sanfilippo received his B.A. and MSc in physics from the University of Pennsylvania, and his M.D. and Ph.D. from Duke University, where he also did his residency training and joined the faculty from 1979-1992, rising to professor of Pathology, Immunology, and Experimental Surgery.
From 1993-2000, Sanfilippo was the Baxley Professor and Chair of the Department of Pathology at Johns Hopkins, and led the formation of the Johns Hopkins Comprehensive Transplant Center, for which he was the director of research. In 2000, he joined Ohio State University as CEO of the Medical Center, Senior VP for Health Sciences, and Dean of the College of Medicine and Public Health. With over 280 publications and $20 million in personal research grant support, he has received numerous awards and recognition for his research and leadership in transplantation, pathology, and academic medicine, has served on the editorial board of 13 professional journals, and been elected president of seven academic and professional organizations.
Randall (Randy) L. SchiestlVice President, R&D
Global Technology & Services
Boston Scientific Corporation
Randall (Randy) L. Schiestl, PMP, is the Vice President, R&D, Global Technology & Services at Boston Scientific Corporation (BSC) where he leads a team focused on minimally invasive medical devices. Schiestl has global responsibility for building technical community, enabling technology partnerships, driving R&D globalization, and implementing global R&D systems. Engineering teams that he directs are located across multiple facilities both US and OUS, and he chairs the cross-divisional Technical Executive Committee within BSC.
Schiestl has a BSME degree from the University of Minnesota, College of Science & Engineering, high distinction. He also holds MBA and Executive MBA degrees from the University of Minnesota, Carlson School of Management. His work history includes Honeywell, Alliant Techsystems, and Boston Scientific.
Schiestl serves on multiple local and national industry advisory boards and consortiums including the Medical Device Industry Consortium, the Medical Industry Leadership Institute, Heart Advisory Committee, Medical Alley, FIRST Robotics plus UMN Biomedical, Medical Device Center, Pediatric Device Innovation Consortium, Nanotechnology Industry Advisory Boards, and the Dean’s Advisory Board. He also serves on the Parker H. Petit Institute for Bioengineering and Bioscience External Advisory Board at the Georgia Institute of Technology. Schiestl received the 2011 UMAA Alumni Service Award from the University of Minnesota, College of Science & Engineering, and the Design of Medical Devices Conference Award in 2012. Schiestl was elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2015.
M. Richard Shen, Ph.D.Founder and Managing Director
RS Technology Ventures LLC
Richard Shen is the founder and managing director of RS Technology Ventures, a strategic advisory and investment company. Founded in 2016, RSTV is focused on the fields of nucleic acid analysis, oncology diagnostics and genomics. Richard is an active member of Tech Coast Angels in San Diego and is advising several early phase startups. Previously, Shen held many senior positions in his 15-year career at Illumina. He has been responsible for Operations, Consumables Product Development and Oncology R&D. As Vice President of Oncology R&D, he led the teams that developed applications for the analysis of tumor genomes. He also guided the team that created the processes for the startup GRAIL, a company focused on detecting early stage cancer from blood samples.
Shen holds several key patents in the fields of nucleic acid analysis and sequencing. One of his patents enabled the development of a process to sequence the human genome for $1,000.
Shen is an alumnus of UCLA (B.S.) and LSU Medical Center (Ph.D.). He did postdoctoral fellowships at University of Michigan Medical Center to study gene therapy and Lawrence Livermore National Laboratories to study variation in DNA repair genes.